NasdaqGM:LRMRBiotechs
Larimar Therapeutics (LRMR) Is Up 85.9% After Breakthrough Status For Nomlabofusp In Friedreich’s Ataxia
In February 2026, Larimar Therapeutics announced that the FDA granted Breakthrough Therapy Designation to nomlabofusp for treating adults and children with Friedreich’s ataxia, while the company advanced plans for an accelerated Biologics License Application supported by skin frataxin as a novel surrogate endpoint.
This combination of expedited regulatory status and FDA alignment on using a new biomarker underscores how central nomlabofusp has become to Larimar’s clinical and regulatory...